Scientists from Bristol Myers Squibb and Lund University have outlined how mechanistic modelling can enhance process development for recombinant adeno-associated virus (rAAV)-based therapies. The modelling allows researchers to rapid identify optimal processing conditions and balance purity and yield. It also supports process characterisation needed for commercial process control strategies and is described as a rapid, flexible method for studying challenging parameter spaces.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
